High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool.

Archive ouverte

Woodrow, Charles J | Dahlström, Sabina | Cooksey, Richard | Flegg, Jennifer A | Le Nagard, Hervé | Mentré, France | Murillo, Claribel | Ménard, Didier | Nosten, François | Sriprawat, Kanlaya | Musset, Lise | Quashie, Neils B | Lim, Pharath | Fairhurst, Rick M | Nsobya, Sam L | Sinou, Veronique | Noedl, Harald | Pradines, Bruno | Johnson, Jacob D | Guerin, Philippe J | Sibley, Carol H | Le Bras, Jacques

Edité par CCSD ; American Society for Microbiology -

International audience. Assessment of in vitro susceptibility is a fundamental component of antimalarial surveillance studies, but wide variations in the measurement of parasite growth and the calculation of inhibitory constants make comparisons of data from different laboratories difficult. Here we describe a Web-based, high-throughput in vitro analysis and reporting tool (IVART) generating inhibitory constants for large data sets. Fourteen primary data sets examining laboratory-determined susceptibility to artemisinin derivatives and artemisinin combination therapy partner drugs were collated from 11 laboratories. Drug concentrations associated with half-maximal inhibition of growth (IC50s) were determined by a modified sigmoid Emax model-fitting algorithm, allowing standardized analysis of 7,350 concentration-inhibition assays involving 1,592 isolates. Examination of concentration-inhibition data revealed evidence of apparent paradoxical growth at high concentrations of nonartemisinin drugs, supporting amendment of the method for calculating the maximal drug effect in each assay. Criteria for defining more-reliable IC50s based on estimated confidence intervals and growth ratios improved correlation coefficients for the drug pairs mefloquine-quinine and chloroquine-desethylamodiaquine in 9 of 11 and 8 of 8 data sets, respectively. Further analysis showed that maximal drug inhibition was higher for artemisinins than for other drugs, particularly in ELISA (enzyme-linked immunosorbent assay)-based assays, a finding consistent with the earlier onset of action of these drugs in the parasite life cycle. This is the first high-throughput analytical approach to apply consistent constraints and reliability criteria to large, diverse antimalarial susceptibility data sets. The data also illustrate the distinct biological properties of artemisinins and underline the need to apply more sensitive approaches to assessing in vitro susceptibility to these drugs.

Suggestions

Du même auteur

Genomic epidemiology of artemisinin resistant malaria

Archive ouverte | Amato, Roberto | CCSD

International audience. The current epidemic of artemisinin resistant Plasmodium falciparum in Southeast Asia is the result of a soft selective sweep involving at least 20 independent kelch13 mutations. In a large g...

A molecular marker of artemisinin-resistant Plasmodium falciparum malaria.

Archive ouverte | Ariey, Frédéric | CCSD

International audience. Plasmodium falciparum resistance to artemisinin derivatives in southeast Asia threatens malaria control and elimination activities worldwide. To monitor the spread of artemisinin resistance, ...

A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms.

Archive ouverte | Ménard, Didier | CCSD

Comment inK13-Propeller Mutations and Malaria Resistance, http://www.nejm.org/doi/full/10.1056/NEJMe1604520. International audience. BACKGROUND:Recent gains in reducing the global burden of malaria are threatened by...

Chargement des enrichissements...